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Sir James Mackenzie, famous for describing the first mechanistic 
insights into AF in 1902 using his polygraph, also reported that AF was 
present in 80–90% of patients who had congestive heart failure (HF) in 
1920.1 Today, the conditions are the two ‘epidemics’ of cardiovascular 
disease.2 They are dominating cardiovascular care and, with increasing 
longevity, they will become more prevalent and place an even greater 
burden upon healthcare resources over the coming decades.3, 4 The 
conditions are inextricably linked in a vicious cycle, with HF promoting 
the development of AF and vice versa. In addition, each increases the 
morbidity and mortality associated with the other.5 
Despite good progress in the management of AF-related symptoms, 
there are limited data to compare the benefits of different treatments 
and international guidelines advocate multiple therapeutic options.6 
Traditionally, AF rhythm control involves a combination of antiarrhythmic 
medical therapy and direct current cardioversion (DCCV). Partly 
because of the inefficacy of these therapies the ‘rate versus rhythm’ 
debate has been intense in the aftermath of trials showing that, 
compared to a rate control strategy, a rhythm control strategy does not 
reduce mortality or morbidity and is more costly and inconvenient.7, 8 
More recently, multiple studies have reported improvements in ‘soft’ 
end points with catheter ablation while two trials – Catheter Ablation vs 
Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial (CABANA; 
NCT00911508) and Catheter Ablation vs Standard Conventional 
Treatment in Patients With LV Dysfunction and AF (CASTLE-AF) – have 
reignited the debate as to whether modern rhythm control therapy can 
improve prognosis in patients with AF.
This paper is a state-of-the-art review analysing world literature 
accessed via detailed literature searches utilising PubMed, Web of 
Science and Scopus to establish the connection between AF and HF in 
detail and to determine the impact of AF rhythm control on patients 
with coexisting HF. 
Direct Current Cardioversion for AF 
and Left Ventricular Performance 
In 1962, Lown described electrical cardioversion of AF.9 He later won 
the Nobel Prize for his nuclear weapon non-proliferation work.10 
Electrical cardioversion is indicated for patients with AF associated 
with significant symptoms or as part of a long-term rhythm control 
strategy. The efficacy and immediacy of DCCV in restoring SR provides 
valuable insight into the potential benefit of rhythm control on cardiac 
performance.
Kieny et al. demonstrated that, after successful cardioversion in 
persistent AF patients with dilated cardiomyopathy, left ventricular 
ejection fraction (LVEF) improved from 32.1% ±€5.3% to 52.9 ±€9.7%; 
p<0.001.11 Wall et al. demonstrated an improvement in LVEF of 14.2% in 
patients with impaired LV function following successful cardioversion 
(n=108; 95% CI [11.0%–17.4%]; p<0.0001). Furthermore, the benefit was 
more significant the lower the LVEF. The subgroup analysis of moderately 
reduced ejection fraction (HFmrEF) showed a mean improvement of 
4.24% (n=50; 95% CI [0.3–8.2%]; p=0.03) and the subgroup analysis 
of reduced ejection fraction (HFrEF) showed a mean improvement of 
23.0% (n=58; 95% CI [19.4–26.6%]; p<0.0001). 
DCCV successfully restores SR in the majority of patients who 
undergo the procedure with quoted success rates at the time of the 
procedure of the order of 85%.12 However, it is widely accepted that 
DCCV has limited long-term success rate with only 30–40% of 
patients remaining in SR at the end of 1 year.13 Restoration of SR with 
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DCCV can improve AF-related symptoms, LVEF, exercise capacity and 
HF symptoms.14,15 
Given the greater efficacy of AF ablation and antiarrhythmic drug (AAD) 
therapy in maintaining SR, it is logical to hypothesise a more substantial 
role for these interventions in patients with coexisting HF and AF. 
Despite this, the only indication in international guidelines for catheter 
and surgical AF ablation (including concomitant open and closed 
procedures and standalone) remains symptom relief.16
Antiarrhythmic Medication for 
AF in Heart Failure 
Two landmark studies, each with >1,000 patients, have assessed the 
efficacy of pharmacological rhythm control in patients with 
concomitant AF and HF (AF-CHF) with HFrEF.17 In the Danish 
Investigators of Arrhythmia and Mortality on Dofetilide in Congestive 
Heart Failure (DIAMOND-CHF) trial, 1,518 patients were randomised to 
receive either dofetilide (n=762) or placebo (n=758). At the conclusion 
of the trial (12 months follow-up), 65% of patients in the dofetilide arm 
were in SR versus 30% of patients in the placebo arm. There was no 
difference in mortality between the two groups, but the dofetilide arm 
had lower rates of HF hospitalisation than the placebo group.18
In the AF-CHF trial, there was no difference in cardiovascular death 
when comparing a rate versus rhythm-control strategy with 
antiarrhythmic medications in 1,376 patients with AF and HFrEF and 
New York Heart Association (NYHA) classes II–IV (HR 1.06; 95% CI 
[0.86–1.30]; p=0.59), with similar findings for all-cause mortality and 
worsening HF.19 
A possible explanation for these neutral outcomes is the difficulty in 
achieving and maintaining SR in patients with HF. In the rhythm control 
arm of AF-CHF, although 82% or participants were taking amiodarone, 
58% had at least one episode of AF during the trial.19 In addition, the 
potential benefit of SR maintenance with respect to mortality may have 
been neutralised by harmful effects of AADs.17
Benefits of Rate Control for AF in Heart Failure
A poor rate control resulting in fast ventricular response has been 
suspected as one of the major determinants of HF in AF patients. 
Impaired cardiac function can be reversed after restoration of SR and 
good ventricular rate control achieved as well by using either 
antiarrhythmic drugs or by atrioventricular (AV) node ablation and 
pacemaker implantation.2
While the benefit of cardiac resynchronisation therapy (CRT) is 
established in symptomatic HF patients in SR with LVEF ≤35% and QRS 
duration of ≥120 ms, its role in patients with coexistent HF and AF is 
less well defined.20,21 CRT with AV node ablation provides robust rate 
control and improved ventricular synchrony in AF and requires 
attention. Three studies have evaluated the impact of AV node ablation 
on LVEF in 346 CRT-AF patients.22–24 The mean increase in LVEF was 
10.3% (95% CI [6.4%–14.2%]) in patients receiving a CRT device 
combined with AV node ablation. These data suggest an important role 
for rate control of AF in improving outcomes in HF patients.
Catheter Ablation for AF in Heart Failure 
The first data on the impact of curative catheter ablation for AF in HF 
patients was reported by Hsu et al. in 2004.25 The authors demonstrated 
that LVEF significantly increased after AF ablation with the greatest 
improvement within the first 3 months after the procedure. Interestingly, 
LVEF increased in most of the patients irrespective of whether 
ventricular rates were poor or well-controlled before ablation, indicating 
the existence of other factors than a fast ventricular rate for the 
development of AF-CHF. 
In the Comparison of Pulmonary Vein Isolation Versus AV Nodal 
Ablation With Biventricular Pacing for Patients With Atrial Fibrillation 
With Congestive Heart Failure (PABA CHF; NCT00599976) study, 41 
patients with drug-resistant AF were randomly assigned to pulmonary 
vein isolation (PVI) and 40 patients to undergo AV node ablation 
combined with biventricular pacing.26 At 6 months, patients who had 
undergone PVI had a higher LVEF than those who had received AV 
node ablation and biventricular pacing (35% versus 28%; p<0.011). 
Patients undergoing the rhythm control procedure also had better 
6-minute walk distance (340 m versus 297 m; p<0.001) than those in 
the ‘ablate and pace’ strategy. In patients undergoing PVI, 71% 
remained in SR at 6 months. AV node ablation with biventricular 
pacing is a robust form of the rate-control strategy and of rate 
regularisation. PABA  CHF showed that PVI, compared to the best 
possible rate-control and rate-regularisation strategy, provides 
superior morphological and functional improvements. Potential 
explanations for LVEF improvement might be the improvement of 
atrial contractility, maintenance of atrioventricular synchrony, as well 
as the prevention of high ventricular rates.27
Importance of Sinus Rhythm
A number of recent trials have suggested that SR following AF 
ablation is associated with improved outcomes in patients with AF.28 
Substantial data demonstrate that restoration of SR leads to an 
improvement in LVEF in AF patients (Table 1).29 Regardless of 
aetiology, LV systolic dysfunction and HF are  associated with a 
higher risk of death.30 The majority of AF ablation trials use freedom 
from AF and restoration of SR as their primary endpoints, with 
procedural success rates of 50–60% after a single procedure and 
80–85% after repeat procedures.31 Therefore, it is logical to postulate 
that, in restoring SR, a successful AF ablation may not only improve 
LVEF but also reduce the excess mortality associated with 
concomitant HF.
In studies of catheter ablation of AF, restoration of SR is associated with 
significant improvements in LVEF, with an 11% increase on average.32 In 
addition, patients with AF and HF who spend a higher proportion of 
time in SR experience less severe functional impairment (NYHA class III 
symptoms in 27 versus 35%; p<0.0001).33 
Myocardial Fibrosis in AF and Heart Failure
Atrial fibrosis leads to structural and functional impairment of the left 
atrium and persistence of AF, and is associated with the development 
of AF-HF.34,35 Mild pre-ablation left atrial structural remodelling by 
delayed enhancement MRI (DEMRI) predicts favourable structural and 
functional reverse remodelling and long-term success after catheter 
ablation of AF, irrespective of the paroxysmal or persistent nature 
of AF.34 
Despite extensive research addressing the interplay between changes 
in the atria and AF, relatively few studies provide histological evaluation 
of the ventricle in patients with AF.36 However, it appears to have a 
crucial role in the AF-CHF interaction. Ventricular fibrosis may occur 
secondary to AF as a consequence of rapid ventricular rates, the 
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irregularity of ventricular contraction or activation of the renin–
angiotensin–aldosterone system.35,37,38 Myocardial interstitial fibrosis 
contributes to left ventricular dysfunction leading to the development 
of HF.39 Successful catheter ablation has been shown to result in 
reverse remodelling and a regression of diffuse fibrosis in AF-mediated 
cardiomyopathy providing the pathophysiological explanation for the 
benefit of ablation in AF-CHF patients.40 
Cardiac MRI offers noninvasive assessment of atrial injury and recovery 
of active atrial function following AF ablation because of its ability to 
visualise all segments of the atrial wall during the cardiac cycle.41 
Catheter ablation can be associated with sustained atrial dysfunction 
owing to to ablation-related scarring. Previous studies have 
demonstrated that the difference between electroanatomic mapping 
(EAM) ablated area and LGE-MRI scar area was associated with higher 
AF recurrence after ablation.42 Despite the aforementioned benefits of 
catheter ablation in AF-CHF, repeat ablation could be associated with 
more ablation-related scarring and worse outcomes.43,44 This suggests 
timely treatment of arrhythmia-mediated cardiomyopathy may minimise 
irreversible ventricular remodelling if SR is restored and multiple AF 
ablation procedures should be avoided. 
Cardiopulmonary Exercise Testing 
in AF and Sinus Rhythm
Cardiopulmonary exercise testing (CPET) is an important tool to 
evaluate exercise capacity and predict outcomes in patients with 
HF.45 It provides an assessment of the integrative exercise responses 
involving the pulmonary, cardiovascular and skeletal muscle systems, 
which are not adequately reflected through the measurement of 
individual organ system function.45 Peak oxygen uptake (VO
2 
peak) is 
an important, reproducible facet of exercise performance and has 
been shown to have high prognostic value in cardiac patients and 
healthy individuals. VO
2 
peak is determined by cellular oxygen 
demand and equates to the maximal rate of
 
oxygen transport. 
Significant increases in VO
2 
peak in SR have been demonstrated on 
CPET in patients who have undergone AF ablation.46 These findings 
imply that an improvement in haemodynamics in SR improves the 
rate of oxygen transport and, ultimately, this has the potential to 
improve prognosis. In addition, VO
2
 peak is a strong prognostic 
indicator in chronic HF and is a criterion variable for consideration of 
cardiac transplantation in such patients.47,48 Among patients with 
chronic systolic HF, even a modest increase in peak VO
2
 peak over 
3  months has been associated with more favourable outcomes, 
highlighting the importance of CPET as an investigative tool; it also 
provides an insight into the favourable haemodynamic effects of 
restoring SR with an ablation procedure.49 
Sleep Studies and Rhythm Control
Another condition strongly associated with AF is sleep-disordered 
breathing (SDB). Perhaps the most straightforward explanation for the 
association is that patients with AF and SDB share a number of risk 
factors and comorbidities, including age, male sex, hypertension, HF 
and coronary artery disease. 
More evidence is emerging of a true physiological connection.50,51 
Patients with obstructive sleep apnoea (OSA) have >30% greater risk of 
AF recurrence after catheter ablation than those without.52–54 However, 
the efficacy of catheter ablation for AF is similar in patients without 
obstructive sleep apnoea and those with this condition who are on 
continuous positive airway pressure treatment.55,56 
In an animal model, obesity and acute obstructive apnoea have been 
shown to interact to promote AF.57 OSA is associated with repetitive 
forced inspiration against a closed airway which can result in negative 
intrathoracic pressure leading to an increase in cardiac afterload, larger 
atrial size and higher wall stress, resulting in atrial remodelling, which 
predisposes patients to arrhythmia.58
Further recent studies have demonstrated a reduction in nocturnal 
respiratory events (apnoeas and hypopnoeas) and a reversal of sleep-
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disordered breathing with restoration of SR using both DCCV and AF 
ablation procedures at short-term follow-up.55,56 Improving haemodynamic 
status and cardiac function with restoration of SR could reduce fluid 
displacement from the lower limbs to the neck region of the body, a key 
mechanism in the pathogenesis of OSA.59–61 The hazard of mortality in 
sleep apnoea increases with apnoea severity, highlighting the potential 
importance of these findings and providing a further, different angle to 
hypotheses supporting a mortality benefit of SR in patients with AF.62  
AF Ablation and Mortality in Heart Failure
A number of studies postulate that AF ablation can reduce mortality. 
CASTLE-AF is the only randomised clinical trial to date comparing 
catheter ablation and pharmacological therapy for patients with 
coexisting HF and AF that measures the ‘hard’ primary endpoints of 
death and hospitalisation for heart failure.63 Patients had symptomatic 
paroxysmal or persistent AF, LVEF ≤35%, NYHA class ≥2, with an ICD or 
CRT with defibrillator implanted. AF ablation was associated with a 
significantly lower rate of a composite of death and hospitalisation for 
HF than medical therapy.63 There was also a benefit in all-cause 
mortality alone, driven by a significantly lower rate of cardiovascular 
death in the ablation group. 
Furthermore, catheter ablation reduced the AF burden, increased the 
distance walked in 6 minutes and improved the LVEF. On the basis of the 
data extracted from the memory of the implanted devices, 63.1% of the 
patients in the ablation group and 21.7% in the medical-therapy group 
(p<0.001) were in SR at the 60-month follow-up visit and had not had AF 
recur since the previous follow-up visit (typically at 48 months).63
Heart Rhythm Monitoring Following AF Ablation
Given the benefits of maintenance of SR following AF ablation 
described, accurate and complete heart rhythm monitoring is 
imperative. The HRS Expert Consensus Statement set guidelines for 
catheter ablation trials stating that, after the blanking period, success is 
defined as ‘freedom from AF, atrial flutter or tachycardia’ and 
discontinuation of antiarrhythmic medication, that patients should be 
followed for at least 12 months and, at minimum, should have a 24-
hour Holter monitor at 3, 6, 12 and 24 months.16,64 
The gold standard of heart rhythm monitoring is beat-to-beat monitoring 
with implanted devices.65 AF ablation studies employing beat-to-beat 
monitoring with implanted devices have determined ‘cure’ rates of only 
29% for persistent AF, significantly lower than trials that used less 
stringent monitoring criteria.31, 66 Beat-to-beat monitoring will detect 
significantly more AF episodes because of the continuous monitoring 
capabilities of implanted devices. In the absence of large, prospective, 
randomised studies using beat-to-beat follow up, ablation success 
remains open to speculation. Beat-to-beat monitoring is particularly 
important if it is the restoration of SR that is associated with 
improvement in LV function and provides an argument for all catheter 
ablation studies to have significantly tighter cardiac monitoring, ideally 
with implanted devices allowing every heartbeat to be monitored. 
Discussion
The main findings of our systematic review are that the 
pathophysiological benefits from AF ablation stem from successful 
restoration of SR and this is most likely to be achieved by early 
intervention. These benefits extend to reversed remodelling of the left 
cardiac chambers, an improvement in LVEF, an improvement in key, 
prognostic facets of exercise performance and a reduction in SDB. It is 
likely that these factors are the drivers for the reduced mortality 
observed with AF ablation in the recent CASTLE-AF study. 
In addition, a large percentage of patients in the general population 
progress from a paroxysmal form of AF to a persistent or permanent 
form, limiting the likelihood of successful ablation, suggesting timely 
treatment of arrhythmia-mediated cardiomyopathy with ablation may 
minimise irreversible remodelling when SR is restored. 
Finally, given the importance of restoration and maintenance of SR 
following ablation, we propose that AF ablation trials should use stringent 
heart rhythm monitoring, ideally with implanted devices, allowing 
monitoring of every heartbeat to document the true impact of ablation on 
heart rhythm. Long-term monitoring with an implanted device allows for 
determination of AF pattern, number of discrete episodes and AF burden, 
providing a wealth of information regarding a patient’s AF. 
Recent evidence has suggested the importance of AF burden to 
cardiovascular and neurological outcomes, and the effect of lifestyle and 
risk factor modification on AF burden. AF burden is best defined as the 
proportion of time an individual is in AF during a monitoring period, 
expressed as a percentage, and continuous monitoring, ideally with an 
implanted device, is required to meet this definition. 
A number of studies have reported improvement in ‘soft’ end points with 
catheter ablation of AF. However, they are not powered to demonstrate 
that mortality can be reduced by ablation. The CASTLE-AF trial substantiates 
these earlier reports that AF ablation is beneficial in patients with AF and 
HF. The study demonstrated that the use of ablation for AF in patients with 
HF is associated with a significantly lower composite of death and HF 
hospitalisation than medical therapy. The results from CASTLE-AF are of 
significant interest and support a role for AF ablation in such patients. 
However, these results do not support offering AF ablation to all patients 
with AF and HF. The inclusion criteria for the trial were strict, resulting in 
more than 3,000 patients being screened to identify 363 patients to take 
part in the trial. The quality of the rate control in the pharmacological group 
has not been published and, in the current review, we have demonstrated 
the importance of effective rate control in improving LV performance. The 
mortality benefits of ablation only appeared after 3 years into the trial, by 
which stage only 191 of the original trial patients were still being followed 
up. Finally, some subgroups did not benefit from ablation, such as those 
with an LVEF<25%.67 However, despite these issues, there is sufficient 
evidence to support early AF ablation in patients with symptomatic AF and 
HF, in addition to device therapy. 
The Future
A significant limitation of all AF ablation studies is the lack of blinding 
with regard to randomisation and treatment. Randomised, double-
blind, placebo-controlled studies are considered the gold standard of 
studies involving a medical intervention. Randomised clinical trials with 
inadequate blinding report enhanced placebo effects for intervention 
groups and nocebo effects for placebo groups.68 
It is difficult to perform a truly blinded trial with a sham AF ablation 
procedure, but the lack of blinding could result in bias as to whether, for 
example, to admit a patient for worsening HF, how the patients are 
medically managed, how the patients report symptoms and so on.  To 
date, no studies have included a satisfactory, ethically justifiable sham 
limb to compare with AF ablation. The advent of such a study design 
could advance our understanding to another level. 
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